Skip to main content

Table 3 Percentage of difference of PET parameters in non-responder group

From: A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions

Type of lesions

SUVmax

SUVmean

Isocontour (Bq/mL)

Isocontour-mediastinal

activity (Bq/mL)

Malignant lesion

−4.71

−4.89

−16.36

−12.98

Gastrointestinal cancer

−5.88

−4.68

−11.64

−8.74

Hepatobiliary and pancreatic cancer

−6.71

−4.64

−17.34

−8.48

Hepatocellular carcinoma

−1.64

−5.30

−25.52

−26.99

Inflammatory lesion

−10.21

−6.17

−32.22*

−45.70*

  1. *P < 0.05 when compared parameters between the first day and second day